These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Decitabine studies in chronic and acute myelogenous leukemia. Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691 [No Abstract] [Full Text] [Related]
3. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
4. Evidence for a role of decitabine in the treatment of myeloid sarcoma. Gornicec M; Wölfler A; Stanzel S; Sill H; Zebisch A Ann Hematol; 2017 Mar; 96(3):505-506. PubMed ID: 27817041 [No Abstract] [Full Text] [Related]
5. Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine. Daitoku S; Aoyagi T; Takao S; Tada S; Kuroiwa M Intern Med; 2018 Oct; 57(20):2995-2999. PubMed ID: 29780114 [TBL] [Abstract][Full Text] [Related]
6. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218 [No Abstract] [Full Text] [Related]
7. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582 [No Abstract] [Full Text] [Related]
8. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213 [No Abstract] [Full Text] [Related]
9. Leukemia cells directly phagocytose blood cells in AML-associated hemophagocytic lymphohistiocytosis: a case report and review of the literature. Hatano K; Nagai T; Matsuyama T; Sakaguchi Y; Fujiwara S; Oh I; Muroi K; Ozawa K Acta Haematol; 2015; 133(1):98-100. PubMed ID: 25226795 [No Abstract] [Full Text] [Related]
10. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia]. Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117 [No Abstract] [Full Text] [Related]
11. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722 [No Abstract] [Full Text] [Related]
12. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy. Delavigne K; Bérard E; Bertoli S; Corre J; Duchayne E; Demur C; Mansat-De Mas V; Borel C; Picard M; Alvarez M; Sarry A; Huguet F; Récher C Haematologica; 2014 Mar; 99(3):474-80. PubMed ID: 24142998 [TBL] [Abstract][Full Text] [Related]
13. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299 [TBL] [Abstract][Full Text] [Related]
14. The euphoria of hypomethylating agents in MDS and AML: is it justified? Sekeres MA Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530 [TBL] [Abstract][Full Text] [Related]
15. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313 [TBL] [Abstract][Full Text] [Related]
16. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416 [TBL] [Abstract][Full Text] [Related]
17. Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation. Ustun C; Kalla A; Farrow S; DeRemer DL; Jillella A Am J Hematol; 2008 Oct; 83(10):825-7. PubMed ID: 18767131 [No Abstract] [Full Text] [Related]
18. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Tong X; Li J; Zhou Z; Zheng D; Liu J; Su C Leuk Lymphoma; 2015 Jun; 56(6):1911-3. PubMed ID: 25426665 [No Abstract] [Full Text] [Related]
19. Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Yánez L; Bermúdez A; Richard C; Bureo E; Iriondo A Leukemia; 2009 Jul; 23(7):1342-3. PubMed ID: 19322208 [No Abstract] [Full Text] [Related]
20. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]